Table 3.
Summary of clinical characteristics of 16 cases
| No | Age/Sex | Site of involvement | Symptom | Symptom duration (months) | Histology (WHO classification) | Stage | Operation | Chemotherapy | Radiation dose (cGy) | Response to induction | Overall survival (months) | Disease-free survival (months) | Current status (cause of death) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/49 | Mandible, femur | submandible mass | 3 | diffuse follicular center | IVEA | CHOP | 4500 | CR | 94 | 87 | alive | |
| 2 | M/24 | T8, L5, S1 spine, femur, ilium, skull | back pain | 1 | diffuse mixed small and large B cell (Working formulation) | IVEA | MACOP-B IMVP16 DHAP Steroid pulse |
4080 | CR | 28 | 20 | death (marrow failure, pneumonia, brain hemorrhage) | |
| 3 | M/49 | Rib, C spine, T spine, L spine, skull | fever | 2 | T cell rich B cell (large B cell, variant) | IVEB | M-BACOP, IMVP-16, HOAP-Bleo | none | CR | 108 | 97 | alive | |
| 4 | M/20 | Clavicle, skull, femur, L1 | back pain | 4 | precursor B lymphoblastic leukemia/lymphoma | IVEB | MACOP-B | none | NR | 3 | death (panperitonitis) | ||
| 5 | M/27 | T spine, L spine | back pain | 10 days | diffuse large B cell | IVEA | laminectomy | CHOP HOAP-Bleo IMVP-16 |
3550 | CR | 32 | 15 | alive |
| 6 | M/40 | Ilium | pelvic pain | 8 | diffuse large B cell | uncertain | none | none | 12 | death | |||
| 7 | M/47 | Humerus, femur, skull, TLS spine, ilium | back pain, voiding difficulty | 2 | diffuse large B cell | IVEA | CVP | 3000 | NR | 2 | death (pneumonia) | ||
| 8 | M/64 | Sacrum, sternum | coccyx pain, voiding difficulty | 1 | diffuse large B cell | uncertain | none | none | 15 | death (pneumonia) | |||
| 9 | M/29 | Sternum, T spine | sternal pain, back pain | 3 | diffuse large B cell | IVEA | M-BACOD | 6000 | PR | 22 | death (PCP pneumonia, AIDS) | ||
| 10 | M/21 | Rib, T spine, sacrum, ilium | Fever | 1.5 | Hodgkins disease (mixed cellularity) | IVEB | ABVD | 2520 | PR | 5 | alive | ||
| 11 | F/59 | Tibia | tibia pain | 1 | diffuse large B cell | IIEA | ampulation | VCR+ADR+ Endoxan+ Dactinomycin |
6000 | NR | 7 | death (brain hemorrhage) | |
| 12 | F/63 | Femur | fracture | 1 day | diffuse large B cell | uncertain | none | none | 3 | death (liver cirrhosis, HCC, pneumonia) | |||
| 13 | F/63 | Scapula | shoulder mass | 4 | diffuse large B cell | IIEA | CEOP | 4500 | CR | 19 | 12 | alive | |
| 14 | F/71 | Ulna | elbow pain | 12 | diffuse large B cell | IIEA | M-BACOP | 5040 | CR | 28 | 20 | alive | |
| 15 | F/44 | Femur | knee pain, swelling | 5 | diffuse large B cell | IEA | M-BACOP | 6000 | CR | 60 | 53 | alive | |
| 16 | F/1 | Scapula | scapular mass | 20 days | peripheral T cell, unspecified | IEA | BECOP | none | PR | 10 | alive |
CR, complete remission; PR, partial remission; NR, no response; PCP, Pneumocystis carinii pneumonia; AIDS, acquired immunodeficiency syndrome; HCC, hepatocellular carcinoma;
CHOP, cyclophosphamide, adriamycin, vincristine, and prednisolone; MACOP-B, methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone, and bleomycin, HOAP-Bleo; adriamycin, vincristine, cytosine arabinoside, prednisolone, and bleomycin, IMVP-16; ifosfamide, methothrexate, and etoposide, CVP; cyclophosphamide, vincristine, and prednisolone, CEOP; cyclophosphamide, epirubicin, vincristine, and prednisolone; M-BACOP(D), methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisolone (dexamethasone); DHAP, dexamethasone, cytarabine, and cisplatin; BECOP, bleomycin, epirubicin, cyclophosphamide, vincristine, prednisolone; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine